{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:11:01Z","timestamp":1790655061612,"version":"4.1.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T00:00:00Z","timestamp":1649289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"abstract":"<jats:p>Obesity and\/or metabolic diseases are frequently associated with chronic kidney disease and several factors associated with obesity may contribute to proteinuria and extracellular matrix production. Mineralocorticoid receptor antagonists have proven their clinical efficacy in diabetic kidney disease with preclinical data suggesting that they may also be efficient in non-diabetic chronic kidney disease associated to metabolic diseases. In the present study we developed a novel mouse model combining severe nephron reduction and High Fat Diet challenge that led to chronic kidney disease with metabolic alterations. We showed that the Mineralocorticoid Receptor antagonist canrenoate improved metabolic function, reduced albuminuria and prevented the synergistic effect of high fat diet on renal fibrosis and inflammation in chronic kidney disease mice.<\/jats:p>","DOI":"10.3389\/fphys.2022.859812","type":"journal-article","created":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T08:02:05Z","timestamp":1649318525000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice"],"prefix":"10.3389","volume":"13","author":[{"given":"Roberto","family":"Palacios-Ramirez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ixchel","family":"Lima-Posada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bonnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Genty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaya","family":"Fernandez-Celis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Hartleib-Geschwindner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Foufelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Lopez-Andres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krister","family":"Bamberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Jaisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1097\/01.ASN.0000141963.04540.3E","article-title":"Overview: Obesity: What Does it Have to Do with Kidney Disease?","volume":"15","author":"Abrass","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/00041552-200205000-00010","article-title":"Obesity and Renal Disease","volume":"11","author":"Adelman","year":"2002","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1093\/NDT\/GFAA062","article-title":"Phosphoinositide 3-kinase \u03b3 Deficiency Attenuates Kidney Injury and Fibrosis in Angiotensin II-Induced Hypertension","volume":"35","author":"An","year":"2020","journal-title":"Nephrol. Dial. Transpl."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/nejmoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"72","DOI":"10.24272\/J.ISSN.2095-8137.2017.055","article-title":"Application of Animal Models to Explore the Mechanism of Action and Potential Therapeutic Targets in Renal Disease","volume":"39","author":"Bao Yinwu","year":"2018","journal-title":"Zool. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/dom.13969","article-title":"Pathophysiologic Mechanisms in Diabetic Kidney Disease: A Focus on Current and Future Therapeutic Targets","volume":"22","author":"Barrera\u2010Chimal","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","article-title":"The Myeloid Mineralocorticoid Receptor Controls Inflammatory and Fibrotic Responses after Renal Injury via Macrophage Interleukin-4 Receptor Signaling","volume":"93","author":"Barrera-Chimal","year":"2018","journal-title":"Kidney Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid Receptor Antagonists and Kidney Diseases: Pathophysiological Basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/S41581-021-00490-8","article-title":"Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease - Mechanistic and Therapeutic Effects","volume":"18","author":"Barrera-Chimal","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41440-019-0211-0","article-title":"Effect of a Novel Nonsteroidal Selective Mineralocorticoid Receptor Antagonist, Esaxerenone (CS-3150), on Blood Pressure and Renal Injury in High Salt-Treated Type 2 Diabetic Mice","volume":"42","author":"Bhuiyan","year":"2019","journal-title":"Hypertens. Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.yjmcc.2018.06.008","article-title":"Mineralocorticoid Receptor Antagonism Improves Diastolic Dysfunction in Chronic Kidney Disease in Mice","volume":"121","author":"Bonnard","year":"2018","journal-title":"J. Mol. Cell Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1111\/j.1440-1797.2005.00455.x","article-title":"Role of Aldosterone in Diabetic Nephropathy","volume":"10","author":"Cha","year":"2005","journal-title":"Nephrology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"653601","DOI":"10.3389\/fphys.2021.653601","article-title":"Hydrogen Sulfide Attenuated Sepsis-Induced Myocardial Dysfunction through TLR4 Pathway and Endoplasmic Reticulum Stress","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Physiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s11255-019-02074-9","article-title":"Spironolactone Alleviates Diabetic Nephropathy through Promoting Autophagy in Podocytes","volume":"51","author":"Dong","year":"2019","journal-title":"Int. Urol. Nephrol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1111\/J.1523-1755.2004.00913.X","article-title":"Spironolactone Prevents Early Renal Injury in Streptozotocin-Induced Diabetic Rats","volume":"66","author":"Fujisawa","year":"2004","journal-title":"Kidney Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.3390\/ijms21103587","article-title":"Revisiting Experimental Models of Diabetic Nephropathy","volume":"21","author":"Giralt-L\u00f3pez","year":"2020","journal-title":"Ijms"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1681\/ASN.2005111196","article-title":"Spironolactone Prevents Diabetic Nephropathy through an Anti-inflammatory Mechanism in Type 2 Diabetic Rats","volume":"17","author":"Han","year":"2006","journal-title":"Jasn"},{"key":"B18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1471-2369-15-58","article-title":"Combined Effect of Hyperfiltration and Renin Angiotensin System Activation on Development of Chronic Kidney Disease in Diabetic Db\/db Mice","volume":"15","author":"Hartono","year":"2014","journal-title":"BMC Nephrol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1177\/0192623318799995","article-title":"Synopsis of Sweet! Mouse Models of Diabetic Kidney Disease","volume":"46","author":"Heinz-Taheny","year":"2018","journal-title":"Toxicol. Pathol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/CVR\/CVP191","article-title":"Blockade of Mineralocorticoid Receptor Reverses Adipocyte Dysfunction and Insulin Resistance in Obese Mice","volume":"84","author":"Hirata","year":"2009","journal-title":"Cardiovasc. Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/ki.2014.348","article-title":"Insulin Resistance in Chronic Kidney Disease Is Ameliorated by Spironolactone in Rats and Humans","volume":"87","author":"Hosoya","year":"2015","journal-title":"Kidney Int."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1016\/j.clinthera.2015.05.508","article-title":"Spironolactone Add-On for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-Analysis","volume":"37","author":"Hou","year":"2015","journal-title":"Clin. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1111\/j.1523-1755.2004.00582.x","article-title":"Body Mass index and the Risk of Development of End-Stage Renal Disease in a Screened Cohort","volume":"65","author":"Iseki","year":"2004","journal-title":"Kidney Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"A Randomized Controlled Study of Finerenone versus Placebo in Japanese Patients with Type 2 Diabetes Mellitus and Diabetic Nephropathy","volume":"31","author":"Katayama","year":"2017","journal-title":"J. Diabetes its Complications"},{"key":"B25","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1513\/PATS.200711-168DR","article-title":"Fibrogenesis of Parenchymal Organs","volume":"5","author":"Kisseleva","year":"2008","journal-title":"Proc. Am. Thorac. Soc."},{"key":"B26","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2353\/ajpath.2010.090578","article-title":"eNOS Knockout Mice with Advanced Diabetic Nephropathy Have Less Benefit from Renin-Angiotensin Blockade Than from Aldosterone Receptor Antagonists","volume":"176","author":"Kosugi","year":"2010","journal-title":"Am. J. Pathol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1161\/HYPERTENSIONAHA.118.11873","article-title":"MR (Mineralocorticoid Receptor) Induces Adipose Tissue Senescence and Mitochondrial Dysfunction Leading to Vascular Dysfunction in Obesity","volume":"73","author":"Lefranc","year":"2019","journal-title":"Hypertension"},{"key":"B28","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/J.BIOPHA.2018.07.031","article-title":"Inhibition of IL-18 Reduces Renal Fibrosis after Ischemia-Reperfusion","volume":"106","author":"Liang","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e010310","DOI":"10.1136\/bmjopen-2015-010310","article-title":"Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention of Early Diabetic nephRopathy in TYpe 2 Diabetic Patients with Normoalbuminuria (PRIORITY): Essential Study Design and Rationale of a Randomised Clinical Multicentre Trial","volume":"6","author":"Lindhardt","year":"2016","journal-title":"BMJ Open"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e0129283","DOI":"10.1371\/JOURNAL.PONE.0129283","article-title":"Mefunidone Attenuates Tubulointerstitial Fibrosis in a Rat Model of Unilateral Ureteral Obstruction","volume":"10","author":"Liu","year":"2015","journal-title":"PLoS One"},{"key":"B31","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1046\/J.1523-1755.2003.00058.X","article-title":"Model of Robust Induction of Glomerulosclerosis in Mice: Importance of Genetic Background","volume":"64","author":"Ma","year":"2003","journal-title":"Kidney Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.mcna.2012.10.010","article-title":"Obesity and Diabetic Kidney Disease","volume":"97","author":"Maric-Bilkan","year":"2013","journal-title":"Med. Clin. North America"},{"key":"B33","doi-asserted-by":"publisher","first-page":"12450","DOI":"10.1096\/fj.202000164R","article-title":"The Novel Non\u2010steroidal MR Antagonist Finerenone Improves Metabolic Parameters in High\u2010fat Diet\u2010fed Mice and Activates Brown Adipose Tissue via AMPK\u2010ATGL Pathway","volume":"34","author":"Marzolla","year":"2020","journal-title":"FASEB j."},{"key":"B34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.107.109645","article-title":"Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Prevents Oxidative Stress in Uremic Rats","volume":"52","author":"Michea","year":"2008","journal-title":"Hypertension"},{"key":"B35","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/MCO.0000000000000209","article-title":"Influence of High-Fat Diet on Gut Microbiota","volume":"18","author":"Murphy","year":"2015","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1093\/ndt\/gfp371","article-title":"Increased Renoprotection with ACE Inhibitor Plus Aldosterone Antagonist as Compared to Monotherapies-The Effect on Podocytes","volume":"24","author":"Nemeth","year":"2009","journal-title":"Nephrol. Dial. Transpl."},{"key":"B37","doi-asserted-by":"publisher","first-page":"172537","DOI":"10.1016\/j.ejphar.2019.172537","article-title":"Nephropathy in Diabetic Db\/db Mice Is Accelerated by High Protein Diet and Improved by the SGLT2 Inhibitor Dapagliflozin","volume":"860","author":"N\u00f8rgaard","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1001\/JAMACARDIO.2018.2090","article-title":"Obesity-Associated Heart Failure as a Theoretical Target for Treatment with Mineralocorticoid Receptor Antagonists","volume":"3","author":"Packer","year":"2018","journal-title":"JAMA Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3390\/IJMS22010408","article-title":"Fibrosis in Chronic Kidney Disease: Pathogenesis and Consequences","volume":"22","author":"Panizo","year":"2021","journal-title":"Ijms"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1007\/S11255-019-02291-2","article-title":"The Gut Microbiota and its Relationship with Chronic Kidney Disease","volume":"51","author":"Plata","year":"2019","journal-title":"Int. Urol. Nephrol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1093\/ndt\/17.7.1157","article-title":"Obesity--a Neglected Culprit in Renal Disease","volume":"17","author":"Praga","year":"2002","journal-title":"Nephrol. Dial. Transpl."},{"key":"B42","doi-asserted-by":"publisher","first-page":"112078","DOI":"10.1016\/J.JEP.2019.112078","article-title":"Rhodojaponin II Attenuates Kidney Injury by Regulating TGF-\u03b21\/Smad Pathway in Mice with Adriamycin Nephropathy","volume":"243","author":"Qiu","year":"2019","journal-title":"J. Ethnopharmacology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1159\/000445171","article-title":"Non-transgenic Mouse Models of Kidney Disease","volume":"133","author":"Rabe","year":"2016","journal-title":"Nephron"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mcna.2012.10.001","article-title":"Epidemiology of Diabetic Kidney Disease","volume":"97","author":"Reutens","year":"2013","journal-title":"Med. Clin. North America"},{"key":"B45","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1053\/j.jrn.2006.04.017","article-title":"Renal Disease in Obesity: The Need for Greater Attention","volume":"16","author":"Rutkowski","year":"2006","journal-title":"J. Ren. Nutr."},{"key":"B46","doi-asserted-by":"publisher","first-page":"14098","DOI":"10.1073\/PNAS.0511200103","article-title":"Secondary Lymphoid Tissue Chemokine (SLC\/CCL21)\/CCR7 Signaling Regulates Fibrocytes in Renal Fibrosis","volume":"103","author":"Sakai","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B47","doi-asserted-by":"publisher","first-page":"F1138","DOI":"10.1152\/ajprenal.00315.2002","article-title":"Diabetic Kidney Disease in Thedb\/dbmouse","volume":"284","author":"Sharma","year":"2003","journal-title":"Am. J. Physiology-Renal Physiol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1210\/EN.2016-1040","article-title":"Cardiac Tissue Injury and Remodeling Is Dependent upon MR Regulation of Activation Pathways in Cardiac Tissue Macrophages","volume":"157","author":"Shen","year":"2016","journal-title":"Endocrinology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/jdi.12629","article-title":"Effects of Mineralocorticoid Receptor Antagonists on the Progression of Diabetic Nephropathy","volume":"8","author":"Sun","year":"2017","journal-title":"J. Diabetes Investig."},{"key":"B50","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/KI.2010.177","article-title":"Pivotal Role of CD4+ T Cells in Renal Fibrosis Following Ureteric Obstruction","volume":"78","author":"Tapmeier","year":"2010","journal-title":"Kidney Int."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2017.00313","article-title":"Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis","volume":"8","author":"Tesch","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1093\/ndt\/gfq750","article-title":"Spironolactone Inhibits Hyperglycemia-Induced Podocyte Injury by Attenuating ROS Production","volume":"26","author":"Toyonaga","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"B53","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1172\/JCI41080","article-title":"Myeloid Mineralocorticoid Receptor Controls Macrophage Polarization and Cardiovascular Hypertrophy and Remodeling in Mice","volume":"120","author":"Usher","year":"2010","journal-title":"J. Clin. Invest."},{"key":"B54","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","article-title":"Apararenone in Patients with Diabetic Nephropathy: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Dose-Response Study and Open-Label Extension Study","volume":"25","author":"Wada","year":"2020","journal-title":"Clin. Exp. Nephrol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/S10157-010-0372-2","article-title":"Involvement of Bone-Marrow-Derived Cells in Kidney Fibrosis","volume":"15","author":"Wada","year":"2011","journal-title":"Clin. Exp. Nephrol."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-019-1534-4","article-title":"Spironolactone Ameliorates Endothelial Dysfunction through Inhibition of the AGE\/RAGE axis in a Chronic Renal Failure Rat Model","volume":"20","author":"Wang","year":"2019","journal-title":"BMC Nephrol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/J.KINT.2016.12.034","article-title":"Obesity and Kidney Disease: from Population to Basic Science and the Search for New Therapeutic Targets","volume":"92","author":"Whaley-Connell","year":"2017","journal-title":"Kidney Int."},{"key":"B58","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/J.BIOCHI.2015.08.001","article-title":"Diet-induced Obesity and Kidney Disease - in Search of a Susceptible Mouse Model","volume":"124","author":"Wicks","year":"2016","journal-title":"Biochimie"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1093\/ndt\/gfg427","article-title":"After All Those Fat Years: Renal Consequences of Obesity","volume":"18","author":"Wolf","year":"2003","journal-title":"Nephrol. Dial. Transplant."},{"key":"B60","first-page":"1339","article-title":"An Additive Effect of Eplerenone to ACE Inhibitor on Slowing the Progression of Diabetic Nephropathy in the Db\/db Mice","volume":"8","author":"Zhou","year":"2016","journal-title":"Am. J. Transl. Res."},{"key":"B61","first-page":"606","article-title":"The Selective Mineralocorticoid Receptor Antagonist Eplerenone Is Protective in Mild Anti-GBM Glomeru-Lonephritis","volume":"4","author":"Zitt","year":"2011","journal-title":"Int. J. Clin. Exp. Pathol."}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2022.859812\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T08:02:08Z","timestamp":1649318528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphys.2022.859812\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":62,"alternative-id":["10.3389\/fphys.2022.859812"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2022.859812","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]},"article-number":"859812"}}